论文信息 - Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

The median-effect equation derived from the mass-action law principle at equilibrium-steady state via mathematical induction and deduction for different reaction sequences and mechanisms and different types of inhibition has been shown to be the unified theory for the Michaelis-Menten equation, Hill equation, Henderson-Hasselbalch equation, and Scatchard equation. It is shown that dose and effect are interchangeable via defined parameters. This general equation for the single drug effect has been extended to the multiple drug effect equation for n drugs. These equations provide the theoretical basis for the combination index (CI)-isobologram equation that allows quantitative determination of drug interactions, where CI < 1, = 1, and > 1 indicate synergism, additive effect, and antagonism, respectively. Based on these algorithms, computer software has been developed to allow automated simulation of synergism and antagonism at all dose or effect levels. It displays the dose-effect curve, median-effect plot, combination index plot, isobologram, dose-reduction index plot, and polygonogram for in vitro or in vivo studies. This theoretical development, experimental design, and computerized data analysis have facilitated dose-effect analysis for single drug evaluation or carcinogen and radiation risk assessment, as well as for drug or other entity combinations in a vast field of disciplines of biomedical sciences. In this review, selected examples of applications are given, and step-by-step examples of experimental designs and real data analysis are also illustrated. The merging of the mass-action law principle with mathematical induction-deduction has been proven to be a unique and effective scientific method for general theory development. The median-effect principle and its mass-action law based computer software are gaining increased applications in biomedical sciences, from how to effectively evaluate a single compound or entity to how to beneficially use multiple drugs or modalities in combination therapies.

Ting-Chao Chou | T. Chou

[1] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[2] R Dawson,et al. Mechanism of sodium nitroprusside-mediated inhibition of aromatic amino acid decarboxylase activity. , 1995, Pharmacology.

[3] Ronald J. Tallarida,et al. Statistical analysis of drug combinations for synergism , 1992, Pain.

[4] R. E. Durand,et al. Cisplatin and CCNU synergism in spheroid cell subpopulations. , 1990, British Journal of Cancer.

[5] Arnold J Levine,et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. , 2002, Genes & development.

[6] P Posner,et al. Irreversible binding of acetylethylcholine mustard to cardiac cholinergic muscarinic receptors. , 1986, Molecular pharmacology.

[7] Shu-Yun Cheng,et al. New analogues of AHMA as potential antitumor agents: synthesis and biological activity. , 2003, Bioorganic & medicinal chemistry.

[8] J. Jez,et al. Characterization of the substrate binding site in rat liver 3alpha-hydroxysteroid/dihydrodiol dehydrogenase. The roles of tryptophans in ligand binding and protein fluorescence. , 1996, The Journal of biological chemistry.

[9] D. Schoepp,et al. Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate , 1995, Neuropharmacology.

[10] B. Zemelman,et al. Host response to Escherichia coli heat-labile enterotoxin via two microvillus membrane receptors in the rat intestine , 1989, Infection and immunity.

[11] Stanislaw M. Stepkowski,et al. SYNERGISTIC IMMUNOSUPPRESSIVE ACTIONS OF CYCLOSPORINE WITH A MOUSE ANTI‐RAT α/β‐T CELL RECEPTOR MONOCLONAL ANTIBODY , 1994 .

[12] B D Kahan,et al. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. , 1991, Transplantation.

[13] Huiyun Liang,et al. Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells. , 2004, Molecular cancer therapeutics.

[14] Ting-Chao Chou,et al. Enhanced hydrolytic stability and water solubility of an aromatic nitrogen mustard by conjugation with molecular umbrellas. , 2003, Bioconjugate chemistry.

[15] Jang-Yang Chang,et al. Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation. , 2002, Journal of medicinal chemistry.

[16] J. Brown,et al. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines , 2005, British Journal of Cancer.

[17] W. Bornmann,et al. Reversal of anticancer multidrug resistance by the ardeemins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18] A. Fairlamb,et al. Characterisation of pentamidine-resistant Trypanosoma brucei brucei. , 1995, Molecular and biochemical parasitology.

[19] T. Chou,et al. Determination of availability of ligand binding site at steady state for topological assessment of receptors with the aid of microcomputers , 1990 .

[20] Dwayne D. Hegedus,et al. The Effects of Temperature on the Pathogenicity of Heat-Sensitive Mutants of the Entomopathogenic Fungus,Beauveria bassiana,toward the Migratory Grasshopper,Melanoplus sanguinipes , 1996 .

[21] A. Goldin,et al. DRUG SYNERGISM IN ANTINEOPLASTIC CHEMOTHERAPY. , 1964, Advances in chemotherapy.

[22] N. S. Loumbourdis,et al. Cadmium Accumulation in Liver and Kidneys and Hepatic Metallothionein and Glutathione Levels in Rana ridibunda, After Exposure to CdCl2 , 1998, Archives of environmental contamination and toxicology.

[23] A. Sartorelli,et al. Maintenance of retinoic acid receptor alpha pools by granulocyte colony-stimulating factor and lithium chloride in all-trans retinoic acid-treated WEHI-3B leukemia cells: relevance to the synergistic induction of terminal differentiation. , 2000, Blood.

[24] B. Steele. For More Information , 2000, Journal of the National Cancer Institute.

[25] B D Kahan,et al. Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice. , 1994, Transplantation proceedings.

[26] Hubert Wiener,et al. Rabit distal colon epithelium: II. Characterization of (Na+, K+, Cl−)-cotransport and [3H]-bumetanide binding , 1989, The Journal of Membrane Biology.

[27] B. Sevin,et al. Chemosensitivity testing in gynecologic malignancies and breast cancer , 1994 .

[28] T C Chou,et al. Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. , 1998, Carcinogenesis.

[29] B D Kahan,et al. Synergistic effect of the rapamycin-cyclosporine combination: median effect analysis of in vitro immune performances by human T lymphocytes in PHA, CD3, and MLR proliferative and cytotoxicity assays. , 1991, Transplantation proceedings.

[30] T. Chou,et al. Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro. , 1990, Antiviral research.

[31] A. Tsaroucha,et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. , 1997, Transplant immunology.

[32] T. Chou,et al. Interferon-alpha and 3'-azido-3'-deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure. , 1990, Journal of acquired immune deficiency syndromes.

[33] P. Laneuville,et al. bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. , 1994, Cancer research.

[34] T. Chou,et al. In Vitro Anti-HIV-1 Synergy between Non-Nucleoside Reverse Transcriptase Inhibitors Nevirapine and Efavirenz , 2000, Antiviral therapy.

[35] K. Savin,et al. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36] R. Reiffenstein,et al. Application of the isobologram technique for the analysis of combined effects with respect to additivity as well as independence. , 1990, Canadian journal of physiology and pharmacology.

[37] M. Hirsch,et al. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro , 1992, Antimicrobial Agents and Chemotherapy.

[38] T. Chou,et al. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine , 1991, Antimicrobial Agents and Chemotherapy.

[39] T R Kelly,et al. Intercalating agents with covalent bond forming capability. A novel type of potential anticancer agents. 2. Derivatives of chrysophanol and emodin. , 1989, Journal of medicinal chemistry.

[40] S. Sacks,et al. The synergistic effects of betulin with acyclovir against herpes simplex viruses. , 2004, Antiviral research.

[41] T. Chou,et al. Three-drug synergistic inhibition of HIV-1 replication in vitro by 3'-fluoro-3'-deoxythymidine, recombinant soluble CD4, and recombinant interferon-alpha. , 1992, AIDS research and human retroviruses.

[42] W. Cleland,et al. The kinetics of enzyme-catalyzed reactions with two or more substrates or products. II. Inhibition: nomenclature and theory. , 1963, Biochimica et biophysica acta.

[43] Jing Wang,et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. , 2006, Cancer research.

[44] Cynthia Czajkowski,et al. Mapping the Agonist Binding Site of the GABAAReceptor: Evidence for a β-Strand , 1999, The Journal of Neuroscience.

[45] Joseph R. DiPalma,et al. Principles of Drug Action: The Basis of Pharmacology , 1968 .

[46] C. S. McKee. The Determination of Hydrogen Ions , 1928 .

[47] T. Chou,et al. Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation. , 2004, Bioorganic & medicinal chemistry letters.

[48] Y. Nakabeppu,et al. Sensitivity of Escherichia coli (MutT) and human (MTH1) 8-oxo-dGTPases to in vitro inhibition by the carcinogenic metals, nickel(II), copper(II), cobalt(II) and cadmium(II). , 1997, Carcinogenesis.

[49] M. Hirsch,et al. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro , 1994, Antimicrobial Agents and Chemotherapy.

[50] D. Schoepp,et al. Comparison of Excitatory Amino Acid‐Stimulated Phosphoinositide Hydrolysis and N‐[3H]Acetylaspartylglutamate Binding in Rat Brain: Selective Inhibition of Phosphoinositide Hydrolysis by 2‐Amino‐3‐Phosphonopropionate , 1989, Journal of neurochemistry.

[51] C. Nordling. A New Theory on the Cancer-inducing Mechanism , 1953, British Journal of Cancer.

[52] N. Mantel,et al. The employment of combinations of drugs in the chemotherapy of neoplasia: a review. , 1957, Cancer research.

[53] P. Skehan,et al. Membrane-active drugs potentiate the killing of tumor cells by D-glucosamine. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[54] P. Ornstein,et al. Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action. , 1990, The Journal of pharmacology and experimental therapeutics.

[55] P. N. Lee,et al. Cancer and ageing in mice and men. , 1975, British Journal of Cancer.

[56] T. Chou,et al. A rigorous approach to the diagnosis of synergy among combination therapies of immunosuppressive agents , 2001 .

[57] D E Sutherland,et al. Synergistic effect of 15-deoxyspergualin and cyclosporine in prolonging survival of rat cardiac allografts. , 1994, Transplantation proceedings.

[58] G. Pasternak,et al. Sigma1 binding in a human neuroblastoma cell line , 1996, Neurochemical Research.

[59] T. Chou,et al. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication , 1996, Antimicrobial agents and chemotherapy.

[60] P. Sexton,et al. Molecular Pharmacology , 1965, Nature.

[61] T. Chou,et al. Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cells. , 1987, Leukemia research.

[62] F. M. Hack,et al. Modulation of intrinsic in vitro resistance to carboplatin by edatrexate in the A549 human nonsmall cell lung cancer cell line. , 1994, Oncology research.

[63] Patrick J. Hannan,et al. HT-2 toxin, roridin A, T-2 toxin, and verrucarin A mycotoxins inhibit carbon dioxide production by Kluyveromyces marxianus , 1991 .

[64] David Bom,et al. 7-Silylcamptothecins (silatecans): A new family of camptothecin antitumor agents , 1997 .

[65] M. Egorin,et al. Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNA. , 1991, Cancer research.

[66] T. Chou,et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine , 1992, Antimicrobial Agents and Chemotherapy.

[67] A. Perelson,et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[68] M. Kris,et al. Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[69] R. Barrett,et al. Ligand dissociation constants from competition binding assays: errors associated with ligand depletion. , 1987, Molecular pharmacology.

[70] T. Chou,et al. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. , 2005, European journal of biochemistry.

[71] H. Okamura,et al. Effects of the synthesized growth hormone releasing peptide, KP-102, on growth hormone release in sodium glutamate monohydrate-treated low growth rats. , 1996, Life sciences.

[72] H. Turndorf,et al. On the mechanism of the interaction of ketamine and halothane in vitro. , 1992, General pharmacology.

[73] James F. Holland,et al. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells , 2004, Cancer Chemotherapy and Pharmacology.

[74] M. Israel,et al. Effects of N-trifluoroacetyladriamycin-14-O-hemiadipate and radiation on L1210 cells. , 1986, Radiation research.

[75] B. K. Chang,et al. Schedule-dependent interaction of alpha-difluoromethylornithine and cis-diamminedichloroplatinum(II) against human and hamster pancreatic cancer cell lines. , 1987, Cancer research.

[76] T. Chou,et al. Analogues of taurine as stimulators and inhibitors of ATP-dependent calcium ion uptake in rat retina: combination kinetics. , 1989, Molecular pharmacology.

[77] Erik J. Sorensen,et al. Remote Effects in Macrolide Formation Through Ring-Forming Olefin Metathesis: An Application to the Synthesis of Fully Active Epothilone Congeners. , 1997 .

[78] C. I. Bliss. THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[79] D. Richman,et al. In vitro Anti-HIV-1 Activity of sn-2-Substituted 1-O-Octadecyl-sn-Glycero-3-Phosphonoformate Analogues and Synergy with Zidovudine , 2000, Antiviral chemistry & chemotherapy.

[80] N Mantel,et al. Evaluation of combination chemotherapy with three drugs. , 1968, Cancer research.

[81] Amy Zuckerman,et al. Pharmacological characterization of morphine-6-sulfate and codeine-6-sulfate , 1999, Brain Research.

[82] W R Greco,et al. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. , 1990, Cancer research.

[83] Leslie Wilson,et al. Synergistic Suppression of Microtubule Dynamics by Discodermolide and Paclitaxel in Non-Small Cell Lung Carcinoma Cells , 2004, Cancer Research.

[84] B. Smith,et al. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. , 2004, Blood.

[85] M. Dowsett,et al. Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[86] N. Magné,et al. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. , 2004, European journal of cancer.

[87] M Price,et al. Receptor binding of [3H]naloxone benzoylhydrazone: a reversible kappa and slowly dissociable mu opiate. , 1989, Molecular pharmacology.

[88] Susan Band Horwitz,et al. Structure–Activity Relationship of the Epothilones and the First In Vivo Comparison with Paclitaxel† , 1997 .

[89] G. Pasternak,et al. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype. , 1989, The Journal of pharmacology and experimental therapeutics.

[90] T. Chou,et al. Comparison of the mass action law with the power law the probit law and the logit law in dose effect analyses , 1977 .

[91] Ivana Vucenik,et al. Anti-angiogenic activity of inositol hexaphosphate (IP6). , 2004, Carcinogenesis.

[92] Beverly S Mitchell,et al. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. , 2005, Blood.

[93] T. Chou,et al. Uptake, initial effects, and chemotherapeutic efficacy of harringtonine in murine leukemic cells sensitive and resistant to vincristine and other chemotherapeutic agents. , 1983, Cancer research.

[94] Roger M Macklis,et al. Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. , 2005, International Journal of Radiation Oncology, Biology, Physics.

[95] T. Chou,et al. On the total synthesis and preliminary biological evaluations of 15(R) and 15(S) aza-dEpoB: a Mitsunobu inversion at C15 in pre-epothilone fragments. , 2000, Organic letters.

[96] A Gebre-Hiwot,et al. The in-vitro anti-leishmanial activity of inhibitors of ergosterol biosynthesis. , 1993, The Journal of antimicrobial chemotherapy.

[97] M. Hirsch,et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. , 1996, The Journal of infectious diseases.

[98] Christof M. Kramm,et al. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma , 2001, Cancer Gene Therapy.

[99] T. Yorio,et al. Characterization of alpha 2-adrenoceptor binding sites in rabbit ciliary body membranes. , 1994, Investigative ophthalmology & visual science.

[100] Joseph Ciccolini,et al. Taxotere–5′-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells , 2005, Anti-cancer drugs.

[101] J. Merlin,et al. In vitro evaluation of Taxol combined with radiations in human squamous cell carcinoma spheroids. , 1996, Cancer letters.

[102] X. Kong,et al. Preclinical Pharmacology and Pharmacokinetics of the Anti-Hepatitis Virus Agent 2'-Fluoro-5-Ethyl-1-β-D-Arabinofuranosyluracil in Mice and Rats , 1992, Antimicrobial Agents and Chemotherapy.

[103] T. Chou,et al. Synthesis of the acridone alkaloids glyfoline and congeners. Structure-activity relationship studies of cytotoxic acridones. , 1992, Journal of medicinal chemistry.

[104] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[105] T. Chou,et al. Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro. , 1994, Contributions to gynecology and obstetrics.

[106] T. Chou,et al. Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. , 1997, Transplantation proceedings.

[107] Hong Lu,et al. Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies. , 2005, Immunobiology.

[108] W. Lamph,et al. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma , 2004, Breast Cancer Research and Treatment.

[109] J. Woodward,et al. The putative polyamine antagonists ifenprodil and SL 82.0715 enhance dopamine efflux from rat striatal slices independent of NMDA receptor activation. , 1992, European journal of pharmacology.

[110] Chou Ting-Chao Chou,et al. Conservation of laboratory animals by improved experimental design, generalized equations and computer analysis , 1984 .

[111] D. Burk,et al. The Determination of Enzyme Dissociation Constants , 1934 .

[112] D. Schoepp,et al. The Novel Metabotropic Glutamate Receptor Agonist 2R,4R-APDC Potentiates Stimulation of Phosphoinositide Hydrolysis in the Rat Hippocampus by 3,5-dihydroxyphenylglycine: Evidence for a Synergistic Interaction Between Group 1 and Group 2 Receptors , 1996, Neuropharmacology.

[113] Martin S. Hirsch,et al. Strong in Vitro Synergy Between the Fusion Inhibitor T‐20 and the CXCR4 Blocker AMD‐3100 , 2000, Journal of acquired immune deficiency syndromes.

[114] Chien-Fu Lin,et al. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel , 2006, Cancer Chemotherapy and Pharmacology.

[115] Eric Cundliffe,et al. Protein synthesis inhibitors , 1979, Nature.

[116] Bangaru Chandrasekaran,et al. Synchronization of cells in the S phase of the cell cycle by 3′-azido-3′-deoxythymidine: implications for cell cytotoxicity , 2004, Cancer Chemotherapy and Pharmacology.

[117] B D Kahan,et al. THE IMMUNOSUPPRESSIVE ANTAGONISM OF LOW DOSES OF FK506 AND CYCLOSPORINE , 1991, Transplantation.

[118] T C Chou,et al. Biochemical effects of 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil and 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in mouse leukemic cells sensitive and resistant to 1-beta-D-arabinofuranosylcytosine. , 1982, Cancer research.

[119] J M Moerschbaecher,et al. A phencyclidine recognition site is associated with N-methyl-D-aspartate inhibition of carbachol-stimulated phosphoinositide hydrolysis in rat cortical slices. , 1989, Molecular pharmacology.

[120] E. Vaughan,et al. An in vivo evaluation of alpha adrenergic receptors in canine prostate. , 1989, The Journal of urology.

[121] T. Chou,et al. Inhibition of simian varicella virus infection of monkeys by 1-(2-deoxy-2- fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-beta. , 1990, Antiviral research.

[122] T. Chou,et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. , 1999, Cancer research.

[123] Susan Zolla-Pazner,et al. Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu+ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins , 1998, Journal of Virology.

[124] T. Chou,et al. Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity. , 1996, Journal of medicinal chemistry.

[125] B D Kahan,et al. Beneficial effect of graft perfusion with anti-T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus. , 1996, Transplantation.

[126] T. Chou,et al. Synergism and antagonism in chemotherapy , 1991 .

[127] T C Chou,et al. Synergistic interaction of 15-deoxyspergualin and cyclosporine to prolong the survival of rat islet allografts. , 1994, Transplantation proceedings.

[128] M Naguib,et al. Neuromuscular Effects of Rocuronium Bromide and Mivacurium Chloride Administered Alone and in Combination , 1994, Anesthesiology.

[129] P. Molinoff,et al. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum. , 1983, Molecular pharmacology.

[130] T B Johnson,et al. The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase. , 1989, Advances in enzyme regulation.

[131] L. Lennard,et al. Principles of Drug Action. The Basis of Pharmacology , 1991 .

[132] Colin Sumners,et al. Irreversible Binding and Recovery of the Norepinephrine Uptake System Using an Alkylating Derivative of Norepinephrine , 1988, Journal of neurochemistry.

[133] G. Wahlström,et al. Interactions between hexobarbital and thiopental in male rats evaluated with an anaesthesia threshold. , 2009, Acta pharmacologica et toxicologica.

[134] P. Colombani,et al. Drug-drug interaction between cyclosporine and agents affecting calcium-dependent lymphocyte proliferation. , 1989, Transplantation proceedings.

[135] Carsten Müller-Tidow,et al. Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells. , 2003, International journal of oncology.

[136] F. M. Hack,et al. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis , 2004, Cancer Chemotherapy and Pharmacology.

[137] T. Chou,et al. Synthesis of 4-[(1,3-diaminopyrrolo[3′,4′:4,5]pyrido[2,3-d]-pyrimidin-8-yl)benzoyl]-L-glutamic acid as a potential antifolate , 1993 .

[138] Nordling Co. A New Theory on the Cancer-inducing Mechanism , 1953 .

[139] Berenbaum Mc. What is synergy? , 1989, Pharmacological reviews.

[140] A. Hill,et al. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .

[141] T. Chou,et al. Staurosporine and ent-Staurosporine: The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles1 , 1996 .

[142] T. Chou,et al. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. , 1996, AIDS research and human retroviruses.

[143] T. Chou,et al. Overview: DNA Topoisomerase Targeted Anticancer Agents: New Trends and Developments , 1992 .

[144] M. Hirsch,et al. Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells. , 1989, Blood.

[145] D. Richman,et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine , 1991, Antimicrobial Agents and Chemotherapy.

[146] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[147] H. Skipper,et al. Combination therapy: some concepts and results. , 1974, Cancer chemotherapy reports. Part 2.

[148] D R Burton,et al. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. , 2001, Journal of human virology.

[149] M. Puig,et al. Synergistic Interaction of Morphine and Halothane in the Guinea Pig Ileum , 1988, Anesthesiology.

[150] F. Meyskens,et al. Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone a interferon and retinoic acid , 1986, International journal of cancer.

[151] E. Michelotti,et al. Antifungal properties of taxol and various analogues , 1992, Experientia.

[152] J. Lewis,et al. Probit Analysis (3rd ed). , 1972 .

[153] H. Abou-Issa,et al. Combined effects of interferon and steroid hormones on 2',5'-oligoadenylate synthetase activity in chronic lymphocytic leukemia cells. , 1989, Leukemia research.

[154] B D Kahan,et al. Prospects for synergistic immunosuppressive drug therapy in the coming decade. , 1992, Transplantation proceedings.

[155] R. Motzer,et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.

[156] G. Klein,et al. Comparative quantitative electrophysiologic effects of adenosine triphosphate on the sinus node and atrioventricular node. , 1988, The American journal of cardiology.

[157] Jindrich Cinatl,et al. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines , 2004, Biochemical and Biophysical Research Communications.

[158] C Pettinelli,et al. Methodological issues in AIDS clinical trials. Application of the combination index method in the design of a clinical antiretroviral trial: ACTG 068. , 1990, Journal of acquired immune deficiency syndromes.

[159] R F Schinazi,et al. Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis , 1986, Antimicrobial Agents and Chemotherapy.

[160] Joseph Berkson,et al. Approximation of Chi-Square by “Probits” and by “Logits” , 1946 .

[161] C. Calatozzolo,et al. Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines. , 2004, Oncology research.

[162] F. Guillemin,et al. Parameters Affecting Photodynamic Activity of Foscan® or Meta-tetra(hydroxyphenyl)chlorin (mTHPC) In Vitro and In Vivo , 1998, Lasers in Medical Science.

[163] J B Smith,et al. Lowering extracellular pH evokes inositol polyphosphate formation and calcium mobilization. , 1989, The Journal of biological chemistry.

[164] Tomas Radivoyevitch,et al. The interaction between two radiosensitizers: 5-iododeoxyuridine and caffeine. , 2006, Cancer research.

[165] M. Hirsch,et al. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. , 1992, The Journal of infectious diseases.

[166] A. Kremer,et al. The active site of transketolase. Two arginine residues are essential for activity. , 1980, The Journal of biological chemistry.

[167] Skipper He,et al. Combination therapy: some concepts and results. , 1974 .

[168] Ting-Chao Chou,et al. Synthesis of cyclopentanthraquinones: analogs of mitomycin C , 1993 .

[169] B D Kahan,et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. , 1990, Transplantation.

[170] R. A. Gonzales,et al. Alcohol-induced inhibition of N-methyl-d-aspartate-evoked release of [3H]norepinephrine from brain is related to lipophilicity , 1991, Neuropharmacology.

[171] S H Chu,et al. Age and cortisone alter host responsiveness to cholera toxin in the developing gut. , 1989, The American journal of physiology.

[172] R. Schooley,et al. Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon , 1986, Antimicrobial Agents and Chemotherapy.

[173] B. Clarkson,et al. Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors. , 1987, Cancer research.

[174] J J Mooney,et al. Neuronal monoamine reuptake inhibitors enhance in vitro susceptibility to chloroquine in resistant Plasmodium falciparum , 1994, Antimicrobial Agents and Chemotherapy.

[175] T. Chou,et al. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro , 2004, Cancer Chemotherapy and Pharmacology.

[176] Roy E. Byington,et al. Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. , 1991, Disease markers.

[177] J H Goldie,et al. Interaction of etoposide and cisplatin in an in vitro tumor model. , 1987, Cancer treatment reports.

[178] R. Howells,et al. ADVANCES IN CHEMOTHERAPHY , 1982 .

[179] F. Sharom,et al. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. , 1998, The Biochemical journal.

[180] J. Woodward,et al. Ethanol Inhibition of N‐Methyl‐D‐Aspartate‐Stimulated Endogenous Dopamine Release from Rat Striatal Slices: Reversal by Glycine , 1990, Journal of neurochemistry.

[181] A C UPTON,et al. The dose-response relation in radiation-induced cancer. , 1961, Cancer research.

[182] F. Lo‐Coco,et al. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells , 2005, Leukemia.

[183] B D Kahan,et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. , 2001, Journal of the American Society of Nephrology : JASN.

[184] T. Chou,et al. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability. , 1992, Molecular pharmacology.

[185] R. Schooley,et al. Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1. , 1988, The Journal of infectious diseases.

[186] T C Chou,et al. Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline. , 1999, Journal of medicinal chemistry.

[187] R Vertua,et al. Effects of divalent cations on adenosine agonist binding to A1 receptors and non-A1/non-A2 sites in rat cerebral cortex. , 1994, Pharmacology & toxicology.

[188] A. Donson,et al. Tamoxifen radiosensitization in human glioblastoma cell lines. , 1999, Journal of neurosurgery.

[189] Jing Chen,et al. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. , 2005, Blood.

[190] Ann Collier,et al. Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease , 1995, Annals of Internal Medicine.

[191] Ting-Chao Chou. Chemotherapy: Synergism and Antagonism , 2002 .

[192] R Peto,et al. Editorial: Guidelines on the analysis of tumour rates and death rates in experimental animals. , 1974, British Journal of Cancer.

[193] T. Chou,et al. Combinatorial analysis of multiple substrate-multiple product enzyme reactions. , 1972, Journal of theoretical biology.

[194] Walter Jaeger,et al. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. , 2005, Experimental hematology.

[195] J. Gaddum. Probit Analysis , 1948, Nature.

[196] C. Schultz,et al. Cyclic AMP stimulates the cyclic GMP egression pump in human erythrocytes: effects of probenecid, verapamil, progesterone, theophylline, IBMX, forskolin, and cyclic AMP on cyclic GMP uptake and association to inside-out vesicles. , 1998, Biochemistry.

[197] F. Fonnum,et al. Comparison of the Properties of γ‐Aminobutyric Acid and L‐Glutamate Uptake into Synaptic Vesicles Isolated from Rat Brain , 1989, Journal of neurochemistry.

[198] B D Kahan,et al. The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination. , 1993, Transplantation.

[199] J. Bertino,et al. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[200] Susan Band Horwitz,et al. Total Synthesis of (–)‐Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure–Activity Relationships of the Epothilones , 1997 .

[201] W. Stone,et al. Evidence for a possible functional interaction between serotonergic and cholinergic mechanisms in memory retrieval. , 1987, Behavioral and neural biology.

[202] D. Schoepp,et al. LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors , 1997, Neuropharmacology.

[203] P Palatini,et al. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase. , 1981, The Journal of pharmacology and experimental therapeutics.

[204] W. Walker,et al. Development of Intestinal Host Defense: An Increased Sensitivity in the Adenylate Cyclase Response to Cholera Toxin in Suckling Rats , 1989, Pediatric Research.

[205] Goldie Jh,et al. Interaction of etoposide and cisplatin in an in vitro tumor model. , 1987 .

[206] W. R. Thompson,et al. USE OF MOVING AVERAGES AND INTERPOLATION TO ESTIMATE MEDIAN-EFFECTIVE DOSE: I. Fundamental Formulas, Estimation of Error, and Relation to Other Methods. , 1947, Bacteriological reviews.

[207] B. Koehler,et al. Synthesis of Cyclopentanthraquinones: Analogues of Mitomycin C. , 1993 .

[208] Yun Dai,et al. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. , 2004, Molecular cancer therapeutics.

[209] R. Schooley,et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon , 1987, Antimicrobial Agents and Chemotherapy.

[210] A. Brill,et al. Leukemia in Hiroshima atomic bomb survivors. , 1960, Blood.

[211] J. Woodward,et al. Redox Modulation of N‐Methyl‐D‐Aspartate‐Stimulated Neurotransmitter Release from Rat Brain Slices , 1991, Journal of neurochemistry.

[212] P. Armitage,et al. The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis , 1954, British Journal of Cancer.

[213] D. Bylund,et al. Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype. , 1989, The Journal of pharmacology and experimental therapeutics.

[214] Taeyoung Yoon,et al. The Total Synthesis of Dynemicin A Leading to Development of a Fully Contained Bioreductively Activated Enediyne Prodrug , 1996 .

[215] T R Fraser,et al. Lecture on the Antagonism between the Actions of Active Substances , 1872, British medical journal.

[216] M. Clynes,et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). , 1998, European journal of cancer.

[217] Bryan R. G. Williams,et al. Synergistic Activation of Innate Immunity by Double-Stranded RNA and CpG DNA Promotes Enhanced Antitumor Activity , 2004, Cancer Research.

[218] J. Ashford. General models for the joint action of mixtures of drugs. , 1981, Biometrics.

[219] G. Scatchard,et al. THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .

[220] F. Fonnum,et al. Uptake of Glycine into Synaptic Vesicles Isolated from Rat Spinal Cord , 1990, Journal of neurochemistry.

[221] Lu Zhang,et al. The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 , 2004, Cancer Research.

[222] Hermann Katinger,et al. Passive immunization against oral AIDS virus transmission: An approach to prevent mother‐to‐infant HIV‐1 transmission? , 2001, Journal of medical primatology.

[223] G Milano,et al. Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors , 2005, British Journal of Cancer.

[224] Yuman Fong,et al. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. , 2004, The Journal of urology.

[225] R. Dulbecco. Encyclopedia of human biology , 1991 .

[226] J J Woodward,et al. Effects of the putative polyamine antagonists diethylenetriamine and 1,10-diaminodecane on N-methyl-D-aspartic acid-stimulated [3H]norepinephrine release from rat hippocampal slices. , 1993, The Journal of pharmacology and experimental therapeutics.

[227] G. Pasternak,et al. Demonstration of κ3‐Opioid Receptors in the SH‐SY5Y Human Neuroblastoma Cell Line , 1995 .

[228] M. Hirsch,et al. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. , 1990, The Journal of infectious diseases.

[229] W. Cleland,et al. Enzyme kinetics revisited: a commentary on 'The Kinetics of Enzyme-Catalyzed Reactions With Two or More Substrates or Products'. , 1989, Biochimica et Biophysica Acta.

[230] D. Buchsbaum,et al. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity , 2006, Cancer Gene Therapy.

[231] T. Chou,et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[232] K. Maeyama,et al. The Disposition of (R)‐α‐Methylhistamine, a Histamine H3‐Receptor Agonist, in Rats , 1994 .

[233] J. Bolard,et al. Antifungal agents useful in therapy of systemic fungal infections. , 1983, Annual review of pharmacology and toxicology.

[234] J. Jaén,et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[235] María Inés Picollo,et al. INDEPENDENT AND JOINT ACTION OF CIS- AND TRANS-PERMETHRIN IN TRIATOMA INFESTANS (HEMIPTERA: REDUVIIDAE) , 1998 .

[236] J H J Martin,et al. Synergistic antitumour effect of a combination of toremifene and interferon-alpha on ZR-75-1 human breast cancer cells: dependence on interferon-alpha subtype. , 2002, Oncology reports.

[237] Prasad Adusumilli,et al. Up‐regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ134.5 deleted oncolytic herpes virus (G207) , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[238] T. Chou,et al. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. , 1985, Cancer research.

[239] Martin S. Hirsch,et al. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates. , 1999, Journal of acquired immune deficiency syndromes.

[240] T C Chou,et al. Drug combinations: From laboratory to practice , 1998 .

[241] L. M. Ballas,et al. Staurosporine and ent-Staurosporine: The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles. , 1996 .

[242] Abraham Weizman,et al. Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity , 1994, Brain Research.

[243] T. Chou,et al. On the determination of availability of ligand binding sites in steady-state systems. , 1977, Journal of theoretical biology.

[244] M. Baba,et al. Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-alpha. , 2004, Antiviral research.

[245] D. Schoepp,et al. 3,5‐Dihydroxyphenylglycine Is a Highly Selective Agonist for Phosphoinositide‐Linked Metabotropic Glutamate Receptors in the Rat Hippocampus , 1994, Journal of neurochemistry.

[246] A. Hill. The Combinations of Haemoglobin with Oxygen and with Carbon Monoxide. I. , 1913, The Biochemical journal.

[247] M. Netea,et al. Design of efficacy trials of cytokines in combination with antifungal drugs. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[248] M. Rowlands,et al. Inhibition of 17α-hydroxylase/C17-C20 lyase by bifluranol and its analogues , 1989 .

[249] S. Loewe,et al. Die quantitativen Probleme der Pharmakologie , 1928 .

[250] Paul Richardson,et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. , 2004, Blood.

[251] T. Chou,et al. Antagonistic interactions of hexamethylene bisacetamide in combination with 1-beta-D-arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro. , 1988, Leukemia research.

[252] Paul Talalay,et al. Analysis of combined drug effects: a new look at a very old problem , 1983 .

[253] R. Moran,et al. Chapter 5 – Approaches to the Rational Combination of Antimetabolites for Cancer Chemotherapy , 1975 .

[254] Susan Band Horwitz,et al. Stereoselective syntheses and evaluation of compounds in the 8-desmethylepothilone a series: Some surprising observations regarding their chemical and biological properties , 1997 .

[255] T. Chou,et al. Design of antineoplastic agents on the basis of the “2‐phenyl‐naphthalene‐type” structural pattern. 3. synthesis and biological activity evaluation of 5H‐benzo[b]naphtho‐[2,3‐d]pyrrole‐6,11‐dione derivatives , 1996 .

[256] Ursula Creutzig,et al. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. , 2004, International journal of oncology.

[257] M C Berenbaum,et al. Criteria for analyzing interactions between biologically active agents. , 1981, Advances in cancer research.

[258] E. Vaughan,et al. Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. , 1993, The Journal of urology.

[259] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[260] C O NORDLING. Evidence regarding the multiple mutation theory of the cancer-inducing mechanism. , 1955, Acta genetica et statistica medica.

[261] Y. Kimura,et al. Pharmacological studies on the novel antiallergic drug HQL-79: I. Antiallergic and antiasthmatic effects in various experimental models. , 1998, Japanese journal of pharmacology.

[262] T Chou,et al. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. , 1974, Molecular pharmacology.

[263] X. Breakefield,et al. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. , 1999, Cancer research.

[264] T. Chou,et al. Total synthesis and antitumor activity of 12,13-desoxyepothilone F: an unexpected solvolysis problem at C15, mediated by remote substitution at C21. , 2000, The Journal of organic chemistry.

[265] Albert Heim,et al. Cultured human myocardial fibroblasts of pediatric origin: Natural human interferon-α is more effective than recombinant interferon-α 2a in carrier-state coxsackievirus B3 replication , 1995 .

[266] T. Chou,et al. Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil , 1987, Antimicrobial Agents and Chemotherapy.

[267] A. Murray,et al. Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. , 2005, Vaccine.

[268] H VELDSTRA,et al. Synergism and potentiation with special reference to the combination of structural analogues. , 1956, Pharmacological reviews.

[269] C. Korch,et al. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma , 2005, British Journal of Cancer.

[270] T. Chou,et al. Kinetic properties and inhibition of Acinetobacter glutaminase-asparaginase. , 1983, Biochemical pharmacology.

[271] T. Chou,et al. Preclinical pharmacology and pharmacokinetics of the anti-hepatitis virus agent 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil in mice and rats , 1992, Antimicrobial Agents and Chemotherapy.

[272] Alexey Rivkin,et al. On the remarkable antitumor properties of fludelone: how we got there. , 2005, Angewandte Chemie.

[273] K Magyar,et al. Critical evaluation of the in vivo selectivity between hypotensive and platelet antiaggregating actions of iloprost and prostacyclin in beagle dogs. , 1989, Archives internationales de pharmacodynamie et de therapie.

[274] M. Heinrich,et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. , 2004, Blood.

[275] Robert A. Rasmussen,et al. Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge , 2001, Journal of Virology.

[276] R Rode,et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. , 1999, AIDS.

[277] T. Chou,et al. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and recombinant human beta interferon alone and in combination on simian varicella virus infection in monkeys. , 1987, The Journal of infectious diseases.

[278] R. Schooley,et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication , 1987, Science.

[279] S. Loewe,et al. Antagonisms and antagonists. , 1957, Pharmacological reviews.

[280] G Milano,et al. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines , 2001, British Journal of Cancer.

[281] William E Grizzle,et al. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[282] T. Chou,et al. Comparison of dose-effect relationships of carcinogens following low-dose chronic exposure and high-dose single injection: an analysis by the median-effect principle. , 1980, Carcinogenesis.

[283] S. T. Cowan,et al. The strategy of chemotherapy. , 1958 .

[284] Jack J. Fox,et al. Biochemical Effects of 2′-Fluoro-5-methyl-1-β-d-arabinofuranosyluracil and 2′-Fluoro-5-iodo-1-β-d-arabinofuranosylcytosine in Mouse Leukemic Cells Sensitive and Resistant to 1-β-d-Arabinofuranosylcytosine , 1982 .

[285] K Nakatsu,et al. Effect of 5-isosorbide mononitrate on isosorbide dinitrate-induced relaxation of rabbit aortic rings. , 1984, Canadian journal of physiology and pharmacology.

[286] Palmer Taylor,et al. Principles of Drug Action , 1990 .

[287] T. Chou,et al. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: A rationale for combination therapy with chemotherapeutic agents , 1995, International journal of cancer.

[288] T. Chou,et al. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. , 1976, Journal of theoretical biology.

[289] C. Gridelli,et al. Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro? , 2004, Anticancer research.

[290] John Leyden. Webb,et al. Enzyme and metabolic inhibitors , 1963 .

[291] G. Sager,et al. The effect of Mg2+, nucleotides and ATPase inhibitors on the uptake of [3H]-cGMP to inside-out vesicles from human erythrocytes. , 1999, Molecular membrane biology.

[292] T. Chou,et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[293] T. Chou,et al. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. , 1977, The Journal of biological chemistry.

[294] Martin S. Hirsch,et al. Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[295] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[296] Hermann Katinger,et al. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. , 2003, AIDS research and human retroviruses.

[297] Alexey Rivkin,et al. Complex target-oriented total synthesis in the drug discovery process: the discovery of a highly promising family of second generation epothilones. , 2003, Journal of the American Chemical Society.

[298] M. Hirsch,et al. Susceptibility of human cytomegalovirus to two-drug combinations in vitro. , 1996, Antiviral therapy.

[299] B. K. Chang,et al. Enhanced potency of daunorubicin against multidrug resistant subline KB-ChR-8-5-11 by a pulsed magnetic field. , 1997, Anticancer research.

[300] S. Loewe. The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[301] C E Leonard,et al. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. , 1996, Cancer research.

[302] M. Hirsch,et al. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro. , 1997, The Journal of infectious diseases.

[303] A. Söling,et al. Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells , 2003, Cancer Chemotherapy and Pharmacology.

[304] Xiuguo Zhang,et al. Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity. , 2005, Bioorganic & medicinal chemistry.

[305] J B Smith,et al. Ca2+ influx via Na(+)-Ca2+ exchange in immortalized aortic myocytes. I. Dependence on [Na+]i and inhibition by external Na+. , 1992, The American journal of physiology.

[306] R. Martuza,et al. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. , 2006, Journal of the National Cancer Institute.

[307] D. Schoepp,et al. Metabotropic glutamate receptor modulation of cAMP accumulation in the neonatal rat hippocampus , 1993, Neuropharmacology.

[308] Christian Trepo,et al. Antiviral Activities of 2′-Fluorinated Arabinosyl—Pyrimidine Nucleosides , 1988 .

[309] G. Steel,et al. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. , 1979, International journal of radiation oncology, biology, physics.

[310] J R Maisin,et al. Effect of X-rays alone or combined with diethylnitrosamine on cancer induction in mouse liver. , 1987, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[311] B J Berger,et al. Antimalarial activity of novel arylene bis(methylketone) compounds. , 1996, The Journal of infectious diseases.

[312] Laetitia Padovani,et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation , 2005, Molecular Cancer Therapeutics.

[313] R. H. Shanks,et al. Preclinical Evaluation of Gemcitabine Combination Regimens for Application in Acute Myeloid Leukemia , 2005, Clinical Cancer Research.

[314] T. Chou,et al. Models for Drug Development and Drug Resistance , 2007 .

[315] T. Chou,et al. Differential alteration of the anti-HIV-1 effect of phosphorothioate oligonucleotide S-dC28 by AZT, interferon-alpha, and dextran sulfate. , 1991, AIDS research and human retroviruses.

[316] Joseph Berkson,et al. The Application of the Logistic Function to Experimental Data. , 1928 .

[317] B D Kahan,et al. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. , 1996, Transplantation.

[318] T. Chou,et al. 9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. , 1995, Journal of medicinal chemistry.

[319] Taeyoung Yoon,et al. Enediyne Quinone Imines: Truncated, Biologically Active Dynemicin Congeners , 1995 .

[320] Lena Kanter,et al. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. , 2005, Cancer letters.

[321] E. Baba,et al. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. , 2005, Oncology reports.

[322] B. Polsky,et al. Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[323] R. Stuart,et al. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. , 1991, Cancer research.

[324] G. Pasternak,et al. Opiate binding in calf thalamic membranes: a selective mu 1 binding assay. , 1988, Molecular pharmacology.

[325] Lin Ji,et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. , 2004, Journal of the National Cancer Institute.

[326] C. Crumpacker,et al. Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA from herpes simplex virus resistant to 9-beta-D-arabinofuranosyladenine. , 1984, Cancer research.

[327] Dale L. Boger,et al. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice , 2005, Cancer Chemotherapy and Pharmacology.

[328] S. Crooke,et al. Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells. , 1982, Molecular pharmacology.

[329] T C Noonan,et al. Effect of BI-L-239, A-64077 and MK-886 on leukotriene B4 synthesis by chopped guinea pig lung and on antigen-induced tracheal contraction in vitro. , 1992, Prostaglandins.

[330] J. Webster. Encyclopedia of Medical Devices and Instrumentation , 1988 .

[331] Sten Orrenius,et al. Buried alive: a novel approach to cancer treatment , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[332] Donghai Dai,et al. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. , 2005, Cancer research.

[333] Debabrata Banerjee,et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. , 2002, Cancer research.

[334] A. Rahier,et al. Cycloeucalenol-obtusifoliol isomerase. Structural requirements for transformation or binding of substrates and inhibitors. , 1989, European journal of biochemistry.

[335] T C Chou,et al. Rational approach to the clinical protocol design for drug combinations: a review. , 2000, Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi.

[336] T. Yonetani,et al. STUDIES ON LIVER ALCOHOL HYDROGENASE COMPLEXES. 3. MULTIPLE INHIBITION KINETICS IN THE PRESENCE OF TWO COMPETITIVE INHIBITORS. , 1964, Archives of biochemistry and biophysics.

[337] N. Saijo,et al. Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells , 2004, Anti-cancer drugs.

[338] M. Grever,et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. , 2005, Blood.

[339] R. He,et al. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. , 1990, Cancer research.

[340] Xiuguo Zhang,et al. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route. , 2005, Cancer research.

[341] J Sühnel,et al. Evaluation of synergism or antagonism for the combined action of antiviral agents. , 1990, Antiviral research.

[342] G. Pasternak,et al. Identification of a high‐affinity orphanin FQ/nociceptin(1–11) binding site in mouse brain , 1999, Synapse.

[343] Yves Pommier,et al. DNA interaction and topoisomerase II inhibition by the antitumor agent 3'-(9-acridinylamino)-5'-hydroxymethylaniline and derivatives , 1996 .